|Place of Origin:||China|
|Minimum Order Quantity:||Negotiation|
|Packaging Details:||Aluminum Foil Bag, barrel, or drum.|
|Delivery Time:||7-15 working days|
|Payment Terms:||T/T, western union, moneygram|
|Supply Ability:||5 - 25 metric ton per month|
|Other Names:||Febuxostat||Appearance:||White Crystal Powder|
|Application:||Pharmaceuticals API||Cas No.:||144060-53-7|
|Density:||1.31g/cm3||Water Solubility:||0.2 G/L|
|Melting Point:||238-239°(dec.)||Boiling Point:||536.6±60.0 °C(Predicted)|
|Flash Point:||278.3°C||Vapour Pressure:||2.41E-12mmHg At 25°C|
|Storage Condition:||-20°C||Refractive Index:||1.605|
|Package:||25kg/carton Drum||Shelf Life:||2 Years|
pharmaceutical raw materials,
Febuxostat is a new generation of xanthine oxidase inhibitor developed by Japanese company. It is used in the treatment of gout. Its structure is totally different from that of xanthine oxidase inhibitor developed 40 years ago. It is a new and efficient selective inhibitor of non purine xanthine oxidase. Xanthine oxidase is the key enzyme to promote the production of uric acid. Febuxostat can reduce the level of chemical Book uric acid in the blood of gout patients with hyperuricemia. The clinical research shows that the product is safe and effective. The product is metabolized through the liver and does not depend on renal excretion. Therefore, it is not necessary to reduce the dosage of febuxostat in patients with moderate to severe hepatorenal insufficiency. The dosage is 40 mg or 80 mg once a day. It is not recommended to treat gout patients without hyperuricemia. In February 2009, the U.S. Food and Drug Administration (FDA) approved febuxostat for the long-term treatment of gout hyperuricemia.
|Boiling point||536.6±60.0 °C(Predicted)|
|Shelf life||2 Years|
Q1: How long is your delivery time?
A: Prompt shipment after receipt of order confirmation for regular products. Generally it is 1-5 days if the goods are in stock. or it is 5-15 days if the goods are not in stock, it is according to quantity.
Contact Person: Max